VYKAT XR (Diazoxide Choline) Patent Expiration, LOE Window & CMS Spending

VYKAT XR (Diazoxide Choline) by Neurocrine Biosciences: FDA Orange Book core substance LOE 2029-03-05 (last listed 2035-11-12), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $26,640 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNeurocrine Biosciences
FDA Application & PathwayN216665 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-03-05
Last Listed Patent or Exclusivity Date2035-11-12
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($26,640 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.